Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Status of adjuvant endocrine therapy for breast cancer | Breast Cancer Research | Full Text
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium - Annals of Oncology
Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer | Chinese Medical Journal
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
BREAST CANCER - Daily Reporter
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: A meta‐analysis of randomized controlled trials - Wang - 2020 - The Breast Journal - Wiley Online Library
